SPHK1 and prostate cancer: Supporting this finding, Akao et al. demonstrated that SPHK1 activity in chemoresistant prostate cancer cells was significantly increased by treatment with camptothecin in a concentration-dependent manner and that this increment of the activity was due to increased protein and mRNA levels (76).